{"id":11439,"date":"2025-10-03T20:40:29","date_gmt":"2025-10-03T20:40:29","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-quality-of-life-qol\/"},"modified":"2025-10-04T08:27:00","modified_gmt":"2025-10-04T08:27:00","slug":"hupertermia-moju-elukvaliteedile-qol","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/et\/hupertermia-moju-elukvaliteedile-qol\/","title":{"rendered":"H\u00fcpertermia m\u00f5ju elukvaliteedile (QoL): Valu leevendamine, v\u00e4simuse v\u00e4hendamine ja adjuvandid immunoloogilised eelised"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"H\u00fcpertermia m\u00f5ju elukvaliteedile (QoL): Valu leevendamine, v\u00e4simuse v\u00e4hendamine ja adjuvandid immunoloogilised eelised\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrul Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"H\u00fcpertermia, Onkoloogia, III faasi kliiniline uuring, QoL, valu, E-E-A-T\"\n      \/*... FAQPage skeem lisatakse eraldi Korduma Kippuvate K\u00fcsimuste jaotise jaoks *\/\n    }\n<\/script><\/p>\n<article>\n<header>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autoriteet ja Ekspertiis (EEAT): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autorid: <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/et\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, ja <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/et\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">H\u00fcpertermia m\u00f5ju elukvaliteedile (QoL): Valu leevendamine, v\u00e4simuse v\u00e4hendamine ja adjuvandid immunoloogilised eelised<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kaasaegses onkoloogias p\u00fc\u00fctakse v\u00e4hiravis saavutada optimaalne tasakaal<a href=\"https:\/\/andromedichyperthermia.com\/hyperthermia-survival-cancer-patients\/\"> Elluj\u00e4\u00e4muse (OS\/DFS)<\/a> ja <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Elukvaliteedi (QoL) vahel.<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> H\u00fcpertermia (HT) on ainulaadne abimeetod, mis on suurtes kliinilistes uuringutes ( <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/et\/hupertermia-iii-faasi-uuringute\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">III faasi RCT-d<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ) n\u00e4idanud QdL-i paranemist mitmel tasandil: s\u00fcmptomite kontroll, \u00fcldine funktsionaalne seisund ja suurep\u00e4rane ohutusprofiil.<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Peamine Palliatiivne Eelis: Valu Kontroll (A1 taseme t\u00f5endid III faasi kliinilistest uuringutest)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Metastaatiline luuvalu halvendab QdL-i. Lokoregionaalne RF-h\u00fcpertermia, kombineerituna Kiiritusraviga (RT), pakub paremat palliatiivset kontrolli, vastavalt <\/span><\/span><a href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Chi MS ja kolleegide poolt avaldatud III faasi uuringule<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. (2017)[1]:<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL-n\u00e4itaja\/Valu Paranemine<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoteraapia<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + H\u00fcpertermia (HT)<\/span><\/span><\/th>\n<th>QoL-m\u00f5ju<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">T\u00e4ieliku Vastanuse M\u00e4\u00e4r (CR) 3 Kuu Jooksul<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (valu skoor null)<\/span><\/span><\/td>\n<td>7,1 %<\/td>\n<td>37,9 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">533% t\u00f5us t\u00e4ieliku valuleevenduse v\u00f5imaluses.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Valu Leevenduse Kestus<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediaan: 55 p\u00e4eva\/7,9 n\u00e4dalat<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediaan: Ei saavutatud 24 n\u00e4dala juures<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Leevenduse kestus kolmekordistub, v\u00e4hendades s\u00f5ltuvust valuvaigistitest.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2024. aastal <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226?via%3Dihub\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">avaldasid Sahinbas ja kolleegid III faasi uuringu<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> luumetastaaside valu kohta, peamiselt rinna- ja eesn\u00e4\u00e4rmev\u00e4hist, kasutades WBHT wIRA h\u00fcpertermiat lisaks RT-le.[2]<\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Selle uuringu p\u00f5hjal esines k\u00f5ige intensiivsem valu ainult kiiritusravi (RT) saanud r\u00fchmas. Uuring l\u00f5petati p\u00e4rast 61 patsiendi kaasamist, 5 aastat p\u00e4rast esimest kaasamist (aprill 2016 \u2013 veebruar 2021). L\u00f5puks n\u00e4itas CR-m\u00e4\u00e4r RT + WBH r\u00fchmas k\u00f5ige olulisemat erinevust RT-ga monoravis, vastavalt 47,4% vs 5,3%, 2 kuu jooksul p\u00e4rast ravi (P-v\u00e4\u00e4rtus &lt; 0,05). T\u00e4ieliku valuleevenduse aeg oli RT + WBH r\u00fchmas 10 p\u00e4eva, samas kui RT-monoravi r\u00fchmas ei saavutatud l\u00f5pp-punkti. Valu progresseerumist v\u00f5i haiguse stabiilsust t\u00e4heldati pooltel RT-r\u00fchma patsientidest 4 n\u00e4dala jooksul p\u00e4rast ravi. See skoor oli aga RT + WBHT patsientidel kahe kuu jooksul p\u00e4rast ravi nullil\u00e4hedane.<\/span><\/span><\/span><\/p>\n<p><strong class=\"sub-title\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">J\u00e4reldused:\u00a0<\/span><\/span><\/span><\/strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> WBH pluss RT n\u00e4itasid luumetastaasidega patsientidel RT-ga v\u00f5rreldes olulist valuleevenduse suurenemist ja l\u00fchemat reageerimisaega.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL-n\u00e4itaja\/Valu Paranemine<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoteraapia<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + H\u00fcpertermia (WBHT wIRA)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL-m\u00f5ju<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">T\u00e4ieliku Vastanuse M\u00e4\u00e4r (CR) 2 kuu jooksul<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (valu skoor null)<\/span><\/span><\/td>\n<td>5,3 %<\/td>\n<td>47,4 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">894 % t\u00f5us<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * t\u00e4ieliku valuleevenduse v\u00f5imaluses.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Aeg t\u00e4ieliku valuleevenduseni<\/span><\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">ei saavutatud<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">10 p\u00e4eva<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\">Oluline ja Kiire Eelis<\/span><\/strong><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Valu Leevenduse Kestus\u00a0<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediaan: 28 p\u00e4eva\/4 n\u00e4dalat pooltel patsientidel<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediaan: Ei saavutatud 24 n\u00e4dala juures<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Leevenduse kestus * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">suureneb kuus korda<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> *, v\u00e4hendades s\u00f5ltuvust valuvaigistitest.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Funktsionaalse Seisundi Parandamine ja V\u00e4simuse V\u00e4hendamine<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT kasu QdL-ile on otseselt m\u00f5\u00f5detav standardiseeritud k\u00fcsimustikega (EORTC QLQ-C30), n\u00e4idates \u00fcldseisundi paranemist (F\u00fc\u00fcsiline Funktsioon, V\u00e4simus ja \u00c4revus):<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Oluliselt Paranenenud QoL (moduleeritud RF h\u00fcpertermia mHT):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Randomiseeritud kliiniline uuring moduleeritud RF-h\u00fcpertermia (mEHT) kohta Emakakaelav\u00e4hi (LACC) puhul n\u00e4itas pikaajaliste QdL-skooride olulist paranemist, kus patsiendid teatasid parematest tulemustest F\u00fc\u00fcsilise ja Emotsionaalse Funktsiooni skaaladel.[3]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V\u00e4simuse Kontroll ja Immunmodulatsioon:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Kogu Keha H\u00fcpertermia (WBHT) ja HT \u00fcldiselt m\u00f5jutavad kroonilist v\u00e4simust (CRF) positiivselt, moduleerides proinflammatoorseid ts\u00fctokiine (IL-6, TNF-alfa). HT aitab ka pikaajaliselt s\u00e4ilitada ja parandada tulemusi F\u00fc\u00fcsilise ja Emotsionaalse Funktsiooni skaaladel.[4]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kiire Emotsionaalne Taastumine (HIPEC):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> P\u00e4rast suuri kirurgilisi protseduure, mis h\u00f5lmavad HT-d (HIPEC), kipub emotsionaalne QdL kiiresti paranema, alates *3 kuud p\u00e4rast operatsiooni, \u00fcletades sageli algtaseme.[5]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Pikaajaliste QoL-Eeliste Konsolideerimine<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Reaalse elu andmed ja kliinilised uuringud kaugelearenenud v\u00e4hkide korral kinnitavad h\u00fcpertermia rolli QdL-i stabiliseerimisel ja parandamisel pikemas perspektiivis:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kuratiivne M\u00f5ju 12 Kuu Jooksul:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Ulatuslik anal\u00fc\u00fcs patsientide kohta, keda raviti kuratiivse kavatsusega (RCT + HT), n\u00e4itas olulist paranemist, mis s\u00e4ilis *12-kuulise perioodi* jooksul, QdL-i alamskaalades, mis hindasid *Emotsionaalset Funktsiooni, Sotsiaalset Funktsiooni* ja *Uneh\u00e4ireid (SL)*, v\u00f5rreldes EORTC onkoloogilise referentspopulatsiooniga.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Palliatiivne Eelis:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Palliatiivses kontekstis t\u00f5i HT lisamine standardravile kaasa kliiniliselt olulise paranemise *Valus (PA)* ja v\u00e4henemise *Finantsraskustes (FI)* *3 kuud p\u00e4rast ravi*, aidates kaasa paremale \u00fcldisele patsiendi seisundile.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Paranenud QoL Kaugelearenenud Haiguse Korral (Kolorektaalv\u00e4hk):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Uuringus, mis hindas K\u00f5rgsageduslikku H\u00fcpertermiat keemiaravi abiga patsientidel keskmise ja kaugelearenenud staadiumi Kolorektaalv\u00e4higa, n\u00e4itas kombinatsiooni saanud r\u00fchm p\u00e4rast 4 ravits\u00fcklit oluliselt k\u00f5rgemaid (paranenenud) QdL-skoore, demonstreerides, et HT parandab efektiivselt QdL-i, lisaks terapeutilistele efektidele, s\u00e4ilitades samal ajal parema ohutuse.[11]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Adjuvandid Bioloogilised Eelised ja Paremad Terapeutilised Indeksid<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT maksimeerib ravi letaalsust ilma oluliselt suurendamata raske toksilisuse (aste 3-4) riski, s\u00e4ilitades seega k\u00f5rge Terapeutilise Indeksi:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Valideeritud Ohutus (III faasi kliinilised uuringud):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Emakakaelav\u00e4hi metaanal\u00fc\u00fcsid n\u00e4itavad olulise erinevuse puudumist \u00e4gedas v\u00f5i hilises toksilisuses (RR Toksilisus 1.01)[6]. Ohutusprofiil s\u00e4ilib P\u00e4rasoolev\u00e4hi[7] ja K\u00f5hun\u00e4\u00e4rmev\u00e4hi uuringutes.[8]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Organite S\u00e4ilitamine:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> P\u00e4rasoolev\u00e4his suurendab HT lisamine neoadjuvantele keemiaradioteraapiale 5-aastast Kolostoomia Vaba Elluj\u00e4\u00e4mist (CFS) 69,0%-lt 87,7%-le, mis on oluline funktsionaalne QdL-i eelis.[7]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Abscopaalne Efekt (Vaktsiinitaoline):<\/strong> HT k\u00e4ivitab immunogeense rakusurma, vabastades Kuumus\u0161oki Valgud (HSPs), mis aktiveerivad ts\u00fctotoksilisi CD8+ T-rakke. See s\u00fcsteemne immunoloogiline eelt\u00f6\u00f6tlus aitab kaasa j\u00e4\u00e4khaiguse kontrollile ja on oluline adjuvantne eelis.[9]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">J\u00e4reldus: Patsiendikeskne Teraapia<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">H\u00fcpertermia integreerimine onkoloogilisse protokolli on arenenud, t\u00f5endusp\u00f5hine strateegia, mis mitte ainult ei paranda Elluj\u00e4\u00e4must, vaid pakub ka tugevat s\u00fcmptomite kontrolli ja s\u00e4ilitab Elukvaliteedi. Valu leevendamine, v\u00e4simuse kontroll ja suurep\u00e4rane ohutusprofiil teevad HT-st onkoloogilise patsiendi tervikliku ravi olulise elemendi.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kutsume teid konsulteerima meie ekspertidega, et integreerida H\u00fcpertermia oma protokolli, eesm\u00e4rgiga maksimeerida nii efektiivsust kui ka Elukvaliteeti.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EEAT-Garantii:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> See sisu p\u00f5hineb avaldatud andmetel randomiseeritud ja perspektiivsetest III faasi kliinilistest uuringutest, mis kasutavad standardiseeritud Elukvaliteedi m\u00f5\u00f5tmise vahendeid (EORTC QLQ-C30). T\u00e4ielikud viited on integreeritud otsel\u00fcnkidega allikpublikatsioonidele.<\/span><\/span><\/small><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Viited:<\/span><\/span><\/p>\n<ol>\n<li>Chi MS, Yang KL, Chang YC, Ko HL, Lin YH, Huang SC, Huang YY, Liao KW, Kondo M, Chi KH. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87. doi: 10.1016\/j.ijrobp.2017.09.030. Epub 2017 Sep 21. PMID: 29066122.<\/li>\n<li>Faghihi Moghaddam F, Bakhshandeh M, Mofid B, Sahinbas H, Faeghi F, Mirzaei H, Rakhsha A, Yousefi Kashi AS, Sadeghi R, Mahdavi A. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. J Therm Biol. 2024 Feb;120:103804. doi: 10.1016\/j.jtherbio.2024.103804. Epub 2024 Feb 23. PMID: 38460451.<\/li>\n<li>Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers (Basel). 2022 Jan 27;14(3):656. doi: 10.3390\/cancers14030656. PMID: 35158924; PMCID: PMC8833695.<\/li>\n<li>Ostberg, K., et al. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol. 2008 Jul;27(7):849-56. doi: 10.1007\/s10067-007-0785-5. Epub 2007 Oct 20. PMID: 17948286.<\/li>\n<li>Morgan RB, Tun S, Eng OS. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a narrative review. Curr Probl Surg. 2020 Jan;57(1):100693. doi: 10.1016\/j.cpsurg.2019.100693. Epub 2020 Jan 29. PMID: 32063294.<\/li>\n<li>Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5;15(2):346. doi: 10.3390\/cancers15020346. PMID: 36672300; PMCID: PMC9856725.<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). <a href=\"https:\/\/doi.org\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/a><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li>Baronzio, G. F., et al. Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Front Oncol. 2020 Nov 24;10:591932. doi: 10.3389\/fonc.2020.591932. PMID: 33324545; PMCID: PMC7721869.<\/li>\n<li>Linnenbank, W. I., et al. Real-World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radiochemotherapy. Cancers (Basel). 2023 Feb 1;15(3):880. doi: 10.3390\/cancers15030880. PMID: 36765790; PMCID: PMC9954584.<\/li>\n<li>Liu, Z. Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncol Lett. 2019 Jan;17(1):215-220. doi: 10.3892\/ol.2018.9574. Epub 2018 Oct 12. PMID: 30655758; PMCID: PMC6313175.<\/li>\n<\/ol>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autoriteet ja Ekspertiis (EEAT): Autorid: Dr. Veronica Iatan , MD, ja Cristian Gologan M.Sc , Andromedichyperthermia H\u00fcpertermia m\u00f5ju elukvaliteedile (QoL): Valu leevendamine, v\u00e4simuse v\u00e4hendamine ja adjuvandid immunoloogilised eelised Kaasaegses onkoloogias p\u00fc\u00fctakse v\u00e4hiravis saavutada optimaalne tasakaal Elluj\u00e4\u00e4muse (OS\/DFS) ja Elukvaliteedi (QoL) vahel. H\u00fcpertermia (HT) on ainulaadne abimeetod, mis on suurtes kliinilistes uuringutes ( III faasi RCT-d&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[903,34,108],"tags":[904,905,906,132,1054,404,909,910,1055],"class_list":["post-11439","post","type-post","status-publish","format-standard","hentry","category-studii-clinice-et","category-uncategorized-et","category-uudised","tag-calitatea-vietii-et","tag-durere-et","tag-hipertermie-oncologica-et","tag-hupertermia","tag-iii-faasi-kliiniline-uuring","tag-onkoloogia","tag-qol-et","tag-studii-faza-iii-et","tag-valu"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/posts\/11439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/comments?post=11439"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/posts\/11439\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/media?parent=11439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/categories?post=11439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/tags?post=11439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}